Tag results:

NSCLC

IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer with 43% of Patients Surviving Five Years

[AstraZeneca, Inc. (BusinessWire, Inc.)] Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit at five years in patients with unresectable Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT).

PB01 Suppresses Radio-Resistance by Regulating ATR Signaling in Human Non-Small-Cell Lung Cancer Cells

[Scientific Reports] Scientists reported the antitumor effects and mechanism of a novel benzothiazole derivative 4-methoxy-cyclohexane carboxylic acid [2-(3,5-dimethyl-isoxazole-4-yl) sulpanil-benzothiazole-6-yl]-amide (PB01) in radiation-resistant human non-small-cell lung cancer cells.

Novartis Announces Tabrecta® First Published Overall Survival and Updated Overall Response Data in Patients with METex14 Metastatic NSCLC

[Novartis AG] Novartis AG has announced the first published mature overall survival and updated overall response rate data following treatment with Tabrecta® in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14).

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

[Clinical Cancer Research] Researchers examined the ability of patient-derived organoids to predict clinical responses to targeted therapies in individual patients and to identify effective anti-cancer therapies for novel molecular targets.

FDA Approves Rybrevant for Advanced NSCLC with EGFR Mutations

[Clinical Oncology News] The FDA granted accelerated approval to amivantamab-vmjw for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

KLHL38 Involvement in Non-Small Cell Lung Cancer Progression via Activation of the Akt Signaling Pathway

[Cell Death & Disease] Scientists clarified the role of KLHL38 in non-small cell lung cancer (NSCLC). KLHL38 expression was evaluated in tumor and adjacent normal tissues from 241 patients with NSCLC using immunohistochemistry and real-time PCR, and its association with clinicopathological parameters was analyzed.

Popular